> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Revised BE Guidance on Paliperidone Palmitate
- URL: https://www.fdaweb.com/revised-be-guidance-on-paliperidone-palmitate/
- Published: 2016-07-01T12:00:00.000Z
- Updated: 2026-09-14T21:13:04.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5136105

*Federal Register* Notice: FDA is making available a revised document: *Draft Guidance on Paliperidone Palmitate.* The recommendations provide specific guidance on the design of bioequivalence studies to support ANDAs for paliperidone palmitate extended-release injectable suspension. To download the guidance, click [here](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM270384?ref=fdaweb.com). To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-07-01/pdf/2016-15663.pdf?ref=fdaweb.com)